These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 37066200)
1. sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies. Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos R medRxiv; 2023 Apr; ():. PubMed ID: 37066200 [TBL] [Abstract][Full Text] [Related]
2. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567 [TBL] [Abstract][Full Text] [Related]
3. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review. Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338 [No Abstract] [Full Text] [Related]
4. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre longitudinal study (DTG RESIST). Egger M; Sauermann M; Loosli T; Hossmann S; Riedo S; Beerenwinkel N; Jaquet A; Minga A; Ross JL; Giandhari J; Kouyos R; Lessells R medRxiv; 2024 May; ():. PubMed ID: 38952780 [TBL] [Abstract][Full Text] [Related]
5. Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania. Ntamatungiro AJ; Eichenberger A; Okuma J; Vanobberghen F; Ndege R; Kimera N; Francis JM; Kagura J; Weisser M; Open Forum Infect Dis; 2023 Jul; 10(7):ofad321. PubMed ID: 37520425 [TBL] [Abstract][Full Text] [Related]
7. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. Sörstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sönnerborg A; Gisslén M; Yilmaz A Int J Antimicrob Agents; 2018 May; 51(5):733-738. PubMed ID: 29371105 [TBL] [Abstract][Full Text] [Related]
8. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C; Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976 [TBL] [Abstract][Full Text] [Related]
9. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1. Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975 [TBL] [Abstract][Full Text] [Related]
10. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis. Ngoufack Jagni Semengue E; Santoro MM; Ndze VN; Ka'e AC; Yagai B; Nka AD; Dambaya B; Takou D; Teto G; Fabeni L; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J PLOS Glob Public Health; 2022; 2(10):e0000826. PubMed ID: 36962573 [TBL] [Abstract][Full Text] [Related]
11. Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Dow DE; Bartlett JA Infect Dis Ther; 2014 Dec; 3(2):83-102. PubMed ID: 25134686 [TBL] [Abstract][Full Text] [Related]
12. Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa. Chimukangara B; Lessells RJ; Singh L; Grigalionyte I; Yende-Zuma N; Adams R; Dawood H; Dlamini L; Buthelezi S; Chetty S; Diallo K; Duffus WA; Mogashoa M; Hagen MB; Giandhari J; de Oliveira T; Moodley P; Padayatchi N; Naidoo K AIDS Res Ther; 2021 Oct; 18(1):74. PubMed ID: 34656129 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of HIV-1 Integrase Resistance-Related Mutations in African Countries. Branda F; Giovanetti M; Sernicola L; Farcomeni S; Ciccozzi M; Borsetti A Pathogens; 2024 Jan; 13(2):. PubMed ID: 38392840 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695 [TBL] [Abstract][Full Text] [Related]
15. Resistance in patients failing integrase strand transfer inhibitors: a call to replace raltegravir with dolutegravir in third-line treatment in South Africa. Steegen K; van Zyl G; Letsoalo E; Claassen M; Hans L; Carmona S Open Forum Infect Dis; 2019 Aug; 6(10):. PubMed ID: 31433056 [TBL] [Abstract][Full Text] [Related]
16. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875 [TBL] [Abstract][Full Text] [Related]
17. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Oldenbuettel C; Wolf E; Ritter A; Noe S; Heldwein S; Pascucci R; Wiese C; Von Krosigk A; Jaegel-Guedes E; Jaeger H; Balogh A; Koegl C; Spinner CD Antivir Ther; 2017; 22(2):169-172. PubMed ID: 27588613 [TBL] [Abstract][Full Text] [Related]
18. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa. Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype. Salvo PF; Farinacci D; Ciccullo A; Borghi V; Rusconi S; Saracino A; Gennari W; Bruzzone B; Vicenti I; Callegaro A; Di Biagio A; Zazzi M; Di Giambenedetto S; Borghetti A Viruses; 2023 Mar; 15(3):. PubMed ID: 36992471 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study. Santos JR; Casadellà M; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; García-Vallecillos C; Vivancos MJ; Imaz A; Iribarren JA; Hernández-Quero J; Villar-García J; Barrufet P; Paredes R; Front Cell Infect Microbiol; 2023; 13():1187999. PubMed ID: 37434782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]